Learn how weight and metabolic health relate to testosterone, why SHBG matters, and how symptoms and repeat testing guide clinical assessment.
Low testosterone means the amount of testosterone measured in blood falls below a clinical threshold. Hypogonadism is a clinical condition that requires compatible symptoms or signs together with consistently low testosterone. These terms describe related findings, but they are not interchangeable.
This article is for informational purposes and is not medical advice. A qualified clinician should assess personal symptoms and laboratory results before making decisions about further testing or treatment.
The European Association of Urology (EAU) lists 12 nmol/L (3.5 ng/mL) as a reliable threshold for late-onset hypogonadism. This is a clinical threshold rather than a complete laboratory reference range. It should not be presented as a stand-alone diagnosis or a target that every man needs to exceed.
The EAU requires compatible symptoms or signs alongside consistently low testosterone. That distinction prevents a laboratory flag from becoming the entire explanation for a man's health concerns.
Metabolic health matters because it can affect the interpretation of total testosterone. The EAU lists obesity and insulin resistance among factors associated with lower sex hormone-binding globulin, usually shortened to SHBG.
The relevant measurements have different roles in an assessment:
Biologically, the important point is that metabolic conditions may affect SHBG as well as the testosterone result being assessed. A low total testosterone value therefore needs context rather than an automatic assumption about its meaning.
For more background on this pattern, Testostra explains why SHBG belongs in the discussion.
The EAU recommends morning, fasting total testosterone testing with a reliable assay. It also recommends repeat confirmation of a low result before testosterone therapy.
These collection conditions are part of clinical interpretation rather than administrative details. A useful discussion covers when the sample was collected and whether a low finding has been confirmed under the recommended conditions.
Testostra's explanation of why repeat blood testing matters provides further context for that conversation. The practical aim is to establish a reliable finding before trying to explain its cause.
In adult men, the EAU associates hypogonadism with more fat mass and less lean mass. It also identifies low sexual desire as a feature that may warrant further hormonal evaluation in the appropriate clinical setting.
These are different kinds of clinical information. Sexual desire describes an experience, while changes in fat and lean mass describe body composition. Both may belong in an assessment without having the same significance for every patient.
A useful consultation distinguishes between:
The EAU's approach brings these observations together rather than allowing any one of them to determine the diagnosis. Body size is relevant information, but it is not a substitute for describing symptoms.
For a patient, the useful starting point is an accurate account of what has changed and why it matters. That gives the clinician a clinical question to investigate rather than only a number to explain.
The EAU identifies several physiological and health-related contributors to low testosterone. It also supports lifestyle measures in a defined clinical setting. These inputs help explain why a hormone assessment may include more than another testosterone measurement.
The EAU describes obesity as a contributor to functional hypogonadism. It also identifies other health conditions and, in some cases, ageing as contributors.
In obesity, the guideline identifies inflammatory signals and adipocytokines alongside estradiol as possible suppressors of the hypothalamic-pituitary-gonadal axis. This is the hormonal signalling system relevant to testosterone production.
These proposed pathways give clinicians a reason to consider weight during a hormone assessment. They do not establish that body weight is the complete explanation for an individual result.
The word functional also has an important clinical boundary. The EAU treats functional hypogonadism as a diagnosis of exclusion, meaning clinicians should rule out an organic cause rather than assume that excess weight explains low testosterone.
The relationship between weight and testosterone is not necessarily one-way. The EAU associates low testosterone with greater visceral adiposity as well as a pattern of more fat mass and less lean mass. It also describes obesity and related health conditions as contributors to lower testosterone.
A 2026 cross-sectional study published through Springer reported that overweight or obese men had lower total testosterone and a higher prevalence of testosterone deficiency than normal-weight men.
The study's design could not establish causality or determine which came first. Taken together, these sources support an association and possible interacting pathways rather than a universal sequence in which one condition always causes the other.
For clinical discussion, this means weight and hormone findings deserve consideration together. It does not require deciding in advance that either one must be the original cause.
The EAU lists type 2 diabetes and metabolic syndrome among the conditions associated with lower SHBG. Obesity and insulin resistance are also on that list.
This makes metabolic health relevant to two parts of the assessment: possible contributors to low testosterone and the interpretation of total testosterone itself. Those are connected questions, but they are not identical.
A clinician may therefore consider whether SHBG and calculated free testosterone would clarify a low or borderline total result. The purpose is better diagnostic interpretation rather than simply adding more tests.
Testostra's guide to the metabolic context around hormone results offers a broader explanation of these connections.
The EAU recommends reviewing diseases and relevant drugs or substances that may interfere with testosterone production or action. This review belongs alongside consideration of weight and other health conditions.
When testosterone is low, the guideline recommends measuring luteinising hormone (LH) and follicle-stimulating hormone (FSH) to help distinguish types of hypogonadism. It also recommends prolactin testing when low sexual desire or other suggestive features point toward secondary hypogonadism.
These investigations address a different question from whether a man has excess weight: what kind of hormonal problem might be present? They help explain why a clinician may look beyond the most visible potential contributor.
The appropriate tests depend on the clinical assessment. They should not be treated as a self-directed testing package or as a reason to change prescribed medicines without qualified care.
For overweight or obese men with hypogonadism, the EAU recommends lifestyle changes and weight reduction as the first approach. It reports that low-calorie diet and physical activity are associated with increased testosterone.
The guideline describes the average increase as small. That finding does not establish that weight loss will resolve every man's symptoms or bring every low result into the expected range.
The practical discussion is therefore about how weight management fits into the wider assessment. A particular diet or exercise plan should not be presented as a reliable way to reach a chosen testosterone number.
This also keeps expectations clear. Lifestyle measures have a guideline-supported place in this setting, but persistent symptoms or low results still belong in clinical review rather than being dismissed as a failure of effort.
The EAU advises against using testosterone therapy to reduce weight or improve cardiometabolic status. TRT should therefore not be presented as a shortcut for addressing metabolic health.
Its guidance instead emphasizes evaluating weight and other health conditions before starting therapy. Potentially interfering medicines also belong in that evaluation.
This separates two clinical questions: whether a man has confirmed hypogonadism and how his weight or metabolic conditions should be addressed. The answers may inform one another without becoming the same treatment decision.
For men researching TRT, that distinction matters more than the promise of changing a laboratory number. The clinical discussion needs to remain connected to the confirmed diagnosis and the reason treatment is being considered.
Ask your physician: “Do my symptoms and repeat tests support hypogonadism? Would SHBG or calculated free testosterone clarify the result? Which underlying causes need review and how should weight management fit into my care?”
Reducing a hormone assessment to body weight alone can hide important biomarker distinctions, a mistake Testostra avoids by explaining the evidence in context. Its articles clarify SHBG and the difference between free and total testosterone measurements so readers can better understand their results without receiving a diagnosis or a treatment plan.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra